Table 2.
Progression-free survival, overall survival, and the objective response rate according to previous hypertension
| Previous hypertension | Treatment-induced hypertension | n | Median (95% CI) | HRa/ORb (95% CI) |
|---|---|---|---|---|
| OSc | ||||
| Yes | Group A | 16 | 9.23 months (3.61, 12.25) | 0.74 (0.31, 1.77) |
| Group B | 17 | 5.36 months (3.02, 11.04) | ||
| No | Group A | 43 | 8.71 months (5.95, 15.08) | 0.37 (0.21, 0.67) |
| Group B | 33 | 4.07 months (3.32, 5.59) | ||
| PFSd | ||||
| Yes | Group A | 16 | 3.61 months (2.69, 6.83) | 0.86 (0.39, 1.92) |
| Group B | 17 | 3.02 months (2.00, 5.59) | ||
| No | Group A | 43 | 4.17 months (2.63, 5.55) | 0.40 (0.24, 0.68) |
| Group B | 33 | 1.41 months (1.35, 2.76) | ||
| ORRe | ||||
| Yes | Group A | 16 | 12.5% (1.55%, 38.35%) | 0.44 (0.04, 5.36) |
| Group B | 17 | 5.88% (0.15%, 28.69%) | ||
| No | Group A | 43 | 9.30% (2.59%, 22.14%) | 0.30 (0.03, 2.86) |
| Group B | 33 | 3.03% (0.08%, 15.76%) |
aHR, hazard ratio; bOR, odds ratio; cOS, overall survival; dPFS, progression-free survival; eORR, objective response rate.